130 institutions hold shares in ADMA Biologics Inc. (ADMA), with 2.02M shares held by insiders accounting for 2.13% while institutional investors hold 55.70% of the company’s shares. The shares outstanding are 87.70M, and float is at 70.91M with Short Float at 13.61%. Institutions hold 54.51% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Perceptive Advisors Llc with over 16.58 million shares valued at $32.34 million. The investor’s holdings represent 17.54% of the ADMA Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 5.42 million shares valued at $10.58 million to account for 5.74% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 3.97 million shares representing 4.20% and valued at over $7.74 million, while Marshall Wace LLP holds 2.63% of the shares totaling 2.49 million with a market value of $4.86 million.
ADMA Biologics Inc. (NASDAQ: ADMA) is 26.67% higher on its value in year-to-date trading and has touched a low of $1.45 and a high of $4.20 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ADMA stock was last observed hovering at around $2.56 in the last trading session, with the day’s loss setting it -0.09% off its average median price target of $8.00 for the next 12 months. It is also 77.55% off the consensus price target high of $11.00 offered by 5 analysts, but current levels are 58.83% higher than the price target low of $6.00 for the same period.
Currently trading at $2.47, the stock is -4.56% and 6.40% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.98 million and changing -3.52% at the moment leaves the stock -1.43% off its SMA200. ADMA registered -29.43% loss for a year compared to 6-month loss of -1.98%. The firm has a 50-day simple moving average (SMA 50) of $2.4212 and a 200-day simple moving average (SMA200) of $2.3025.
The stock witnessed a 1.65% gain in the last 1 month and extending the period to 3 months gives it a 37.22%, and is -6.79% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.56% over the week and 7.72% over the month.
ADMA Biologics Inc. (ADMA) has around 313 employees, a market worth around $237.12M and $40.30M in sales. Distance from 52-week low is 70.34% and -41.19% from its 52-week high.
ADMA Biologics Inc. (ADMA) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for ADMA Biologics Inc. (ADMA) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 1.80, where 0 rate it as a Hold and 1 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
ADMA Biologics Inc. is expected to release its quarterly report on 05/07/2021 and quarterly earnings per share for the current quarter are estimated at -$0.16 with sales reaching $12.91M over the same period.The EPS is expected to grow by 38.90% this year, but quarterly earnings will post 40.50% year-over-year. Quarterly sales are estimated to grow 7.30% in year-over-year returns.
ADMA Biologics Inc. (ADMA) Insider Activity
A total of 4 insider transactions have happened at ADMA Biologics Inc. (ADMA) in the last six months, with sales accounting for 0 and purchases happening 4 times. The most recent transaction is an insider purchase by DEMSKI MARTHA J, the company’s Director. SEC filings show that DEMSKI MARTHA J bought 2,200 shares of the company’s common stock on Sep 11 at a price of $2.29 per share for a total of $5038.0. Following the purchase, the insider now owns 4200.0 shares.
ADMA Biologics Inc. disclosed in a document filed with the SEC on Sep 10 that Grossman Jerrold B (Director) bought a total of 5,000 shares of the company’s common stock. The trade occurred on Sep 10 and was made at $2.22 per share for $11100.0. Following the transaction, the insider now directly holds 0.16 million shares of the ADMA stock.
Still, SEC filings show that on Sep 08, Mond James (EVP, CSO and CMO) acquired 4,000 shares at an average price of $2.20 for $8800.0. The insider now directly holds 73,174 shares of ADMA Biologics Inc. (ADMA).
ADMA Biologics Inc. (ADMA): Who are the competitors?
The company’s main competitors (and peers) include CEL-SCI Corporation (CVM) that is trading 8.27% up over the past 12 months. Short interest in the company’s stock has fallen -20.1% from the last report on Dec 30, 2020 to stand at a total of 11.59 million short shares sold with a short interest ratio of 2.53.